文献速递冠心病

冠状静脉压力升高降低微血管心绞痛患者微血管阻力:随机临床试验

Coronary Venous Pressure and Microvascular Hemodynamics in Patients With Microvascular Angina: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该盲法、假手术对照、交叉随机临床试验纳入20例微血管心绞痛患者,通过球囊充盈冠状静脉窦升高冠状静脉压力,评估其对微血管阻力的影响。结果显示,球囊充盈显著增加冠状静脉窦压力,并降低充血期远端冠脉压力和平均通过时间,同时降低静息及充血期冠脉阻力。提示升高冠状静脉压力可降低微血管阻力,可能为该病治疗提供新思路。

要点

  • 冠状静脉窦球囊充盈使静息和充血期冠状静脉窦压力分别增加300%和317%。

核心结论

  • 在微血管心绞痛患者中,升高冠状静脉压力可降低微血管阻力。

研究设计与样本

  • 盲法、假手术对照、交叉随机临床试验,纳入20例微血管心绞痛患者,中位年龄69岁,女性11例(55.0%)。
  • 干预为冠状静脉窦内球囊充盈(升高静脉压力)对比右心房内球囊放气(假手术),患者和终末评估者均设盲。

主要发现

  • 球囊充盈使静息和充血期冠状静脉窦压力分别增加300%和317%(均P<.001)。
  • 充血期远端冠脉压力中位数假手术92 mmHg,球囊79 mmHg(P=.01)。
  • 充血期平均通过时间中位数假手术0.39 s,球囊0.26 s(P=.008)。
  • 静息冠脉阻力中位数假手术59 mmHg×s,球囊42 mmHg×s(P=.005)。
  • 主要终点充血期冠脉阻力中位数假手术31 mmHg×s,球囊14 mmHg×s(P<.001)。

关键数值与推荐

  • 微血管功能障碍定义为基于热稀释法的微血管阻力指数>25 mmHg×s。
  • 入选患者为加拿大心血管学会心绞痛分级2-4级的中重度心绞痛。

临床怎么用

  • 对于微血管心绞痛患者,升高冠状静脉压力可能通过降低微血管阻力改善心肌灌注,但需进一步研究验证治疗价值。

局限性

  • 样本量小(20例),为生理终点研究,临床硬终点未评估。
  • 研究人群排除了心外膜冠脉疾病、严重瓣膜病、心肌病、肺或肾脏疾病等,代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of the coronary venous circulation in regulating myocardial perfusion and its potential in treating microvascular angina is unexplored. OBJECTIVE: To evaluate whether an increase in coronary venous pressure modifies microvascular resistance in patients with microvascular angina. DESIGN, SETTING, AND PARTICIPANTS: This was a blinded, sham-controlled, crossover, randomized clinical trial that enrolled participants between November 2021 and January 2023. Participants for this physiology end point study were recruited from the Cardiology Center of the University of Medicine in Mainz, Germany. Patients with moderate/severe angina pectoris (Canadian Cardiovascular Society class 2-4) due to microvascular dysfunction (as defined by the thermodilution-based index of microvascular resistance >25 mm Hg × s). Exclusion criteria were epicardial coronary disease, second- and third-degree atrioventricular block, severe valvular heart disease, cardiomyopathy, and pulmonary or kidney disease. INTERVENTION: Inflation of an undersized balloon placed in the cardiac coronary sinus (CS), hereafter referred to as balloon and the deflated balloon in the right atrium, referred to as sham. Measurements were performed at rest and during maximal coronary hyperemia. Both patients and final assessors were blinded to the randomization sequence. MAIN OUTCOMES AND MEASURES: Hemodynamic parameters, including aortic (Pa) and distal (Pd) coronary pressure, coronary sinus pressure (Pcs), right atrial pressure (Pra), and the mean transit time (inverse of blood flow [Tmn]), were measured. RESULTS: A total of 20 patients (median [IQR] age, 69 [64-75] years; 11 female [55.0%]) were included in the study. Two patients (10%) had diabetes, 6 (30%) had hypercholesterolemia, 15 (75%) had hypertension, and 3 (15%) were active smokers. The inflation of the CS balloon caused a significant increase in CS pressure at rest and during hyperemia (300% and 317% increase, respectively, compared with sham, both P < .001), a decrease in hyperemic distal coronary pressure (median [IQR], sham: 92 [80-100] mm Hg; balloon: 79 [75-93] mm Hg; P = .01) and mean transit time (sham: 0.39 [0.23-0.62] s; balloon: 0.26 [0.17-0.46] s; P = .008). As a result, CS occlusion led to a decrease in both resting coronary resistance (median [IQR], sham: 59 [37-87] mm Hg × s; balloon: 42 [31-67] mm Hg × s; P = .005) and the primary end point hyperemic coronary resistance (mean [IQR], sham: 31 [23-53] mm Hg × s; balloon: 14 [8-26] mm Hg × s; P < .001). CONCLUSION AND RELEVANCE: Increased coronary venous pressure led to a reduction of microvascular resistances in patients with microvascular angina, a mechanism with potential implications for the therapy of this complex disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05034224.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ullrich H, Hammer P, Olschewski M, et al. Coronary Venous Pressure and Microvascular Hemodynamics in Patients With Microvascular Angina: A Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37610757. doi:10.1001/jamacardio.2023.2566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。